Data Fields

The Following list shows the data that is available to approved research projects in addition to the Epidemiology Questionnaire


Table Field Description Available values
BloodSpecimen DateTaken Date the blood was drawn from the participant  
BloodSpecimen NonBloodType Sample type collected if not blood (usually mouthwash)  
BloodSpecimen CurrentlyPregnant Was the participant pregnant at the time the blood was taken  
BloodSpecimen DateLastMenstrual Date of last menstrual period when blood was taken  
BloodSpecimen AveDaysMenstrualCycle Average number of days of menstrual cycle for participant  
BloodSpecimen Menopause Had the participant reached menopause at the time the blood was taken  
BloodSpecimen OCP Was the participant taking the oral contraceptive pill at the time the blood was taken  
 
Cancer CancerSite Site of cancer  
Cancer Laterality Laterality of cancer
Cancer Diagnosed Date diagnosed  
Cancer DiagnosedApprox Was diagnosis date approximate  
Cancer DiagnosisDateUnknown Diagnosis date not able to determined (Diagnosed will not be given if this field is true)  
Cancer VerificationOutcome Was the cancer able to be verified  
 
Death CancerCause Did the participant die from cancer  
Death CancerSite Site of the cancer that contributed to the participant's death  
 
Family UFN Unique family ID  
Family CriteriaOnEntry Straddie criteria the family was recruited on  
Family FamilyReviewDate Date at last family review  
Family CriteriaOnReview Straddie criteria at last review  
 
FamilyMutation Nomenclature Description of classified mutation  
FamilyMutation Gene Gene of classified mutation  
FamilyMutation MutationEffect Effect of classified mutation
 
Haplotype BRCA1 UFN Family number  
Haplotype BRCA1 Kindred type Kindred type  
Haplotype BRCA1 BRCA1 shared/typed BRCA1 shared/typed  
Haplotype BRCA1 Date Date tested  
 
Haplotype BRCA1 and BRCA2 UFN Family number  
Haplotype BRCA1 and BRCA2 Kindred type Kindred type  
Haplotype BRCA1 and BRCA2 BRCA1 shared/typed BRCA1 shared/typed  
Haplotype BRCA1 and BRCA2 Date Date tested  
 
Haplotype BRCA2 UFN Family number  
Haplotype BRCA2 Kindred type Kindred type  
Haplotype BRCA2 BRCA2 shared/typed BRCA2 shared/typed  
Haplotype BRCA2 Date Date tested  
 
Haplotype Neither UFN Family number  
Haplotype Neither Kindred type Kindred type  
Haplotype Neither Date Date tested  
 
Mutation Report Date Date the mutatation was reported  
Mutation Gene Gene tested  
Mutation MutationResult Result of the mutation test (positive or negative)  
Mutation ResultType Diagnostic (clinical) or research (kconfab) mutation test  
Mutation TestMethod The method used for the test  
Mutation Predictive Was the test a predictive test  
Mutation FullScreen Was the whole gene tested  
Mutation Exon13 Was Exon 13 tested  
Mutation LargeDeletion Was the test a search for a large deletion  
Mutation MutationDesc Description of the mutation as given by the testing laboratory  
Mutation FamilyMutation Link to the Family mutation the test relates to  
 
Pathology Prophylactic Was the procedure for prophylactic treatment  
Pathology Side Side of the body the tissue was taken from  
Pathology Report Date Date the report was generated by the pathology laboratory  
Pathology PathologyProcedure Procedure that extracted the sample that was tested  
Pathology PathSampleType Type of tissue that was extracted
Pathology Tumour Did the tested sample contain tumour
Pathology TumourSize Size of tumour found  
Pathology Topography Topography classification (ICD-O description)  
Pathology Morphology Morphology classification (ICD-O description)  
Pathology Behaviour Behaviour classification
Pathology Grade Grade classification  
Pathology Oestrogen Oestrogen receptor test result  
Pathology Progesterone Progesterone receptor test result  
Pathology CA125 CA125 test result  
Pathology HER2 HER2 test result  
Pathology PSA PSA test result  
Pathology Gleason Gleason score  
Pathology NodesTested Number of lymph nodes tested if blank then not detailed in report
Pathology NodesPositive Number of positive lymph nodes  
Pathology DCISMorphology Morphology of any in-situ carcinoma found in addition to invasive  
Pathology DCISGrade Grade of any in-situ carcinoma found in addition to invasive  
 
PathologyReview ReviewDate Date of the pathology review  
PathologyReview SourceLab Pathology laboratory who generated the original pathology report  
PathologyReview TumourSize Tumour diameter recorded on report (mm)  
PathologyReview HR Were hormone receptor tested  
PathologyReview HRMethod Method used to test the hormone receptors
PathologyReview ER Oestrogen receptor “Positive” or “Negative” and quantitative result (if supplied)  
PathologyReview PR Progesterone receptor “Positive” or “Negative” and quantitative result (if supplied)  
PathologyReview LNNumber Number of lymph nodes identified  
PathologyReview MetNum Number of lymph nodes containing metastases  
PathologyReview SentinalSelect Staining results for sentinal nodes
Pathology review has been performed only on 214 slide review samples
 
Person UPN Unique person ID  
Person Gender Gender of participant  
Person StartDate Date the participant's details were added to the database  
Person DOB Date of birth of the participant  
Person DOBUnknown Is the date of birth approximate  
Person DeathDate Date of death of the participant  
Person DeathDateApprox Is the date of death approximate  
Person NoFamilyHistory The participant has no family history of their own  
 
PersonOtherStudy OtherStudy Description of other study the participant is enrolled in  
 
PersonRelation ParentID ID of the participant's parents  
Family pedigrees are also available in .jpg or Progeny format
 
QANormalBreast ArchPattern Silverberg architectural pattern  
QANormalBreast NuclearPleo Silverberg nuclear pleopmorphism  
QANormalBreast Mitotic Silverberg mitotic activity  
QANormalBreast Cellularity Silverberg cellularity  
QANormalBreast Neoplastic % neoplastic component
QANormalBreast Lymph Non-neoplastic component: % lymph
QANormalBreast Stroma Non-neoplastic component: % stroma
QANormalBreast NormalType1Percent Normal epithelium component: % type 1
QANormalBreast NormalType2Percent Normal epithelium component: % type 2
QANormalBreast Necrotic % necrotic component
QANormalBreast Morphology Morphology description  
QANormalBreast records QA results for normal (prophylactic) breast tissue.
 
QANormalOvary Side Tissue laterality  
QANormalOvary SurfaceEpi Presence of surface epithelium  
QANormalOvary EpiAmount Amount of surface epithelium
QANormalOvary Pappilations Presence of surface epithelium papillations  
QANormalOvary PapAmount Amount of epithilium papillations
QANormalOvary Cysts Presence of epithelial inclusion cysts  
QANormalOvary CystAmount Amount of epithilial cysts
QANormalOvary Invaginations Presence of cortical invaginations  
QANormalOvary InvagAmount Amount of cortical invaginations
QANormalOvary Stroma Presence of stroma  
QANormalOvary Follicles Presence of cortext follicles  
QANormalOvary CorpLutea Presence of cortex corpora lutea  
QANormalOvary FollCysts Presence of follicular cysts  
QANormalOvary Rete Presence of rete ovarii  
QANormalOvary Fallopian Presence of fallopian tube  
QANormalOvary Morphology Preservation of morphology
QANormalOvary %Tumour % tumour in sample  
QANormalOvary records QA results for normal (prophylactic) ovarian tissue
 
QAProstate Lab Pathology laboratory from which the slide was sourced  
QAProstate Histology Prostate histology
QAProstate SpecimenType Specimen type
QAProstate SpecimenBiopsyCores If specimen type is biopsy; the number of cores  
QAProstate SpecimenBiopsyCoresTumour If specimen type is biopsy; the number of cores with tumour  
QAProstate TumourVolume Tumour Volume
QAProstate GleasonScore1 Gleason score: primary pattern  
QAProstate GleasonScore2 Gleason score: secondary pattern  
QAProstate PrimaryTumour If no tumour
QAProstate PrimaryTumourT1 Extent of clinically inapparent tumour
QAProstate PrimaryTumourT2 Extent of tumour confined within prostate
QAProstate PrimaryTumourT3 Tumour extends through prostate capsule
QAProstate PrimaryTumourT4 Tumour is fixed or invades adjacent structures  
QAProstate RegionalNodes Status of regional lymph nodes
QAProstate DistantMetastasis Distant metastasis
QAProstate ResectionMargins Involvement of resection margins  
QAProstate Extra-prostatic extension Extent of extra-prostatic extension
QAProstate PerineuralInvasion Presence of perineural invasion  
QAProstate NeurovascularBundles Involvement of neurovascular bundles  
QAProstate Lymphovascular invasion Presence of lymphovascular invasion  
QAProstate NeuroendocrineFeatures Presence of neuroendocrine features  
QAProstate IntraEpithelialNeoplasia Presence of high grade prostatic intraepithelial neoplasia  
QAProstate OtherFeatures Any other histological features
QAProstate records QA results for prostate tissue
 
QATumour TissueType Type of tissue QA'd  
QATumour Grade Tumour grade
QATumour ArchPattern Silverberg architectural pattern (ovary only)  
QATumour NuclearPleo Silverberg nuclear pleopmorphism (ovary only)  
QATumour Mitotic Silverberg mitotic activity (ovary only)  
QATumour Neoplastic % neoplastic component
QATumour Lymph Non-neoplastic component: % lymph
QATumour Stroma Non-neoplastic component: % stroma
QATumour NormalType1Percent Normal component: % type 1
QATumour NormalType2Percent Normal component: % type 2
QATumour Necrotic % necrotic component
QATumour Morphology Morphology description  
QATumour BRCAXReview BRCA-like features (breast only)
QATumour records QA results for tumour tissue (not just breast)
 
SlideReview SourceLab Pathology laboratory from which the slide was sourced  
SlideReview AccessionNumber Laboratory accession number  
SlideReview SlidesExamined Which slides were examined  
SlideReview ObsDate Review date  
SlideReview HistoSubType Histological subtype of invasive carcinoma
SlideReview LobType Lobular type
SlideReview Tubule Extent of tubule formation
SlideReview NuclearPleo Extent of nuclear pleomorphism
SlideReview Mitotic Total mitotic figures in 10 high power fields  
SlideReview MitoticTotal Mitotic score (1, 2 or 3)  
SlideReview Grade Overall grade  
SlideReview SolidSheet % of tumour as solid sheet of cells  
SlideReview Circumference % circumference continuous pushing margin  
SlideReview Necrosis Confluent necrosis (“Present” or “Absent”)  
SlideReview Infiltrate Tumour lymphocytic infiltrate
SlideReview Borders Tumour cells: presence of discernable cell borders  
SlideReview Vesicular Tumour cells: presence of vesicular nuclei  
SlideReview EoNucleoli Tumour cells: presence of prominent eosinophilic nucleoli  
SlideReview DCISMass % DCIS  
SlideReview DCISExtending Is the DCIS extending beyond the confines of the main tumour mass  
SlideReview DCISGrade DCIS nuclear grade
SlideReview DCISNecrosis DCIS necrosis
SlideReview DCISPolarisation Presence of DCIS cell polarisation  
SlideReview DCISArchitecture DCIS architectural pattern (multiple selections)
SlideReview LCIS Presence of LCIS  
SlideReview BRCA1 Is the sample consistent with a BRCA1 phenotype  
Slide review has been performed by a pathologist on 214 slides from BRCAX families
 
TestSensitivity Gene Gene tested  
TestSensitivity Sensitivity Sensitivity of all mutation testing performed on participant
See Senstivitities for a description of each test sensitivity category
 
TissueAliquot TissueSize The aliquot size  
TissueAliquot SampleType Type of sample stored
TissueAliquot Side Side of the body the tissue was taken from  
TissueAliquot Tumour Is there tumour present in the aliquot  
 
TissueCollection TissueType The type of tissue collected  
TissueCollection DateTaken The date the tissue was collected  
TissueCollection Prophylactic Was the tissue removed for prophylactic reasons  
TissueCollection TimeToFrozen The time taken to freeze the tissue  
TissueCollection records details of a surgical collection event. Each collection may be divided into a number of aliquots which are recorded in the TissueAliquot table
 
Treatment Treatment Description of non-cancer-related procedure  
Treatment Reason Was the treatment cancer-related or prophylactic.  
Treatment StartDate Date the treatment began  
Treatment EndDate Date the treatment finished  
Treatment Drug Treatment drug  
Treatment Dose Treatment dose  

Note that specific data can only be provided for participants who were deceased at time of family enrollment, or who have signed a consent form


The following diagram illustrates the relationship between tables